Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Abroad (travel likely)RecruitingPHASE2
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Lymphoblastic Leukemia · BCR-ABL1 Fusion Protein Expression · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Philadelphia Chromosome Positive · Recurrent Acute Lymphoblastic Leukemia · Refractory Acute Lymphoblastic Leukemia · t(9;22)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Elias Jabbour)
Study leads
Elias Jabbour
Principal Investigator
M.D. Anderson Cancer Center